Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26037891 | 1.00 | SNCA (0.60) | SNCAMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL26017855 | 1.00 | SNCA (0.60) | SNCAMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL26017856 | 0.86 | SNCA (0.52) | SNCAMAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL21751939 | 0.86 | SNCA (0.52) | SNCAMAPTKDM4ELMNAALDH1A1 | |
| SCHEMBL26017854 | 0.85 | SNCA (0.51) | SNCAMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL21820208 | 0.85 | SNCA (0.51) | SNCAMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL21771119 | 0.82 | SNCA (0.71) | SNCAMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL21751996 | 0.79 | SNCA (0.58) | SNCAMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL21751821 | 0.77 | SNCA (0.51) | SNCAMAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL21751995 | 0.76 | SNCA (1.00) | SNCAMAPTKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3841100-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | Arvinas Operations, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112912376-A | Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases | 阿尔维纳斯运营股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2020041331-A1 | PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | ARVINAS OPERATIONS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091204-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | SNCA 8/4885MAPT 741/4885KDM4E 2704/4885 |
| US-20200085793-A1 | MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USE | UCHL1, ADRM1, CRBN | SNCA 8/4885MAPT 741/4885KDM4E 2704/4885 |
| US-12594264-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | ADRM1, CRBN, SNCA | SNCA 3/4885MAPT 210/4885KDM4E 1807/4885 |
| US-11707452-B2 | Modulators of alpha-synuclein proteolysis and associated methods of use | UCHL1, ADRM1, CRBN | SNCA 8/4885MAPT 741/4885KDM4E 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.